[go: up one dir, main page]

UY36586A - Heterociclilmetiltienouracilos y uso de los mismos - Google Patents

Heterociclilmetiltienouracilos y uso de los mismos

Info

Publication number
UY36586A
UY36586A UY0001036586A UY36586A UY36586A UY 36586 A UY36586 A UY 36586A UY 0001036586 A UY0001036586 A UY 0001036586A UY 36586 A UY36586 A UY 36586A UY 36586 A UY36586 A UY 36586A
Authority
UY
Uruguay
Prior art keywords
treat
heterociclilmetiltienouracilos
same
prevent
prevent diseases
Prior art date
Application number
UY0001036586A
Other languages
English (en)
Inventor
Dr Bernd Kalthof
Dr Klemens Lustig
Dr Pierre Wasnaire
Dr Michael Härter
Dr Frank Süssmeier
Dr Dirk Kosemund
Dr Martina Delbeck
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY36586A publication Critical patent/UY36586A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a derivados novedosos de tieno[2,3-d]pirimidina-2,4-diona ("tienouracilo") que presentan un tipo particular de sustituyente (azaheterociclil)metilo, a procesos para la preparación de los mismos, al uso de los mismos por sí solos o en combinaciones para tratar y/o prevenir enfermedades y al uso de los mismos para producir medicamentos para tratar y/o prevenir enfermedades, especialmente para tratar y/o prevenir trastornos pulmonares y cardiovasculares y cáncer.
UY0001036586A 2015-03-26 2016-03-14 Heterociclilmetiltienouracilos y uso de los mismos UY36586A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15161165 2015-03-26
EP15174566 2015-06-30
EP15184732 2015-09-10

Publications (1)

Publication Number Publication Date
UY36586A true UY36586A (es) 2016-10-31

Family

ID=55586319

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036586A UY36586A (es) 2015-03-26 2016-03-14 Heterociclilmetiltienouracilos y uso de los mismos

Country Status (24)

Country Link
US (1) US10428083B2 (es)
EP (1) EP3274352B1 (es)
JP (1) JP2018509443A (es)
KR (1) KR20170131540A (es)
CN (1) CN107646035A (es)
AU (1) AU2016236272A1 (es)
BR (1) BR112017020317A2 (es)
CA (1) CA2980646A1 (es)
CL (1) CL2017002390A1 (es)
CO (1) CO2017009656A2 (es)
CR (1) CR20170437A (es)
CU (1) CU20170123A7 (es)
DO (1) DOP2017000212A (es)
EA (1) EA201792134A1 (es)
EC (1) ECSP17064196A (es)
IL (1) IL254476A0 (es)
MX (1) MX2017012308A (es)
PE (1) PE20180116A1 (es)
PH (1) PH12017501758A1 (es)
SG (1) SG11201707577VA (es)
TN (1) TN2017000415A1 (es)
TW (1) TW201700480A (es)
UY (1) UY36586A (es)
WO (1) WO2016150901A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
AU2017329677A1 (en) 2016-09-23 2019-04-18 Bayer Aktiengesellschaft N 3 -cyclically substituted thienouraciles and use thereof
JP6999112B2 (ja) * 2016-11-29 2022-02-04 国立研究開発法人産業技術総合研究所 ２，５－ビス（アミノメチル）フラン二ハロゲン化水素塩及びその製造方法並びに２，５－ビス（アミノメチル）フランの製造方法
AU2019367187A1 (en) 2018-10-24 2021-03-25 Leadxpro Ag Functionalized aminotriazines
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
US20220290122A1 (en) * 2019-02-19 2022-09-15 Whitehead Institute For Biomedical Research Methods and agents for modulating mitochondrial nad levels
CN111825698B (zh) 2019-07-30 2021-10-15 杭州阿诺生物医药科技有限公司 腺苷受体拮抗剂
CN112028891B (zh) 2019-07-30 2022-07-05 厦门宝太生物科技股份有限公司 腺苷受体拮抗剂
CN111875615A (zh) * 2020-07-15 2020-11-03 济南大学 一种甲氧基苄脲类化合物及其用途
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2036171A1 (es) 1970-07-21 1972-01-27
US6140325A (en) 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
TW276256B (es) * 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
US6077814A (en) 1997-02-26 2000-06-20 Hokko Chemical Industry Co., Ltd. 1-Substituted 4-carbamoyl-1,2,4-triazol-5-one derivatives and herbicide
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
ATE253580T1 (de) * 1998-08-28 2003-11-15 Astrazeneca Ab Neue thieno(2,3-d)pyrimidindione, verfahren für ihre herstellung und ihre verwendung in der therapie
JP2002541258A (ja) 1999-04-09 2002-12-03 セル セラピューティクス インコーポレーテッド インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
JP2003531910A (ja) * 2000-05-04 2003-10-28 アストラゼネカ アクチボラグ チエノ［２，３−ｄ］ピリミジンジオン類とそれらの医薬品としての使用
GB2363377B (en) 2000-06-14 2004-06-09 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones and therapeutic uses thereof
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
JP2004518732A (ja) 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US6890923B2 (en) 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
EP1587811A1 (en) * 2003-01-17 2005-10-26 AstraZeneca AB Thienopyridazinones and their use in modulation of autoimmune disease
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US8143270B2 (en) 2004-09-02 2012-03-27 3M Innovative Properties Company 2-amino 1H-in-imidazo ring systems and methods
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
JP2010511628A (ja) * 2006-12-01 2010-04-15 ギリアード・パロ・アルト・インコーポレイテッド Ａ２ａアデノシン受容体アンタゴニスト
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
JP6114189B2 (ja) 2010-07-09 2017-04-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および／または予防のためのその使用
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
MX2013003034A (es) 2010-09-17 2013-08-15 Array Biopharma Inc Lactamas piperidinilo-substituidas como moduladores de gpr119.
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012166700A2 (en) * 2011-05-29 2012-12-06 Lisanti Michael P Molecular profiling of a lethal tumor microenvironment
LT3329919T (lt) 2011-11-11 2020-02-10 Gilead Apollo, Llc Acc inhibitoriai ir jų panaudojimas
GB2523211B (en) * 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
US20130287791A1 (en) * 2012-04-25 2013-10-31 C. Wilson Xu Modulation of histone h2b monoubiquitination and treatment of cancer
MX2015015421A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2015052065A1 (de) * 2013-10-07 2015-04-16 Bayer Pharma Aktiengesellschaft Cyclische thienouracil-carboxamide und ihre verwendung

Also Published As

Publication number Publication date
CN107646035A (zh) 2018-01-30
PE20180116A1 (es) 2018-01-18
US20180065981A1 (en) 2018-03-08
TN2017000415A1 (en) 2019-01-16
SG11201707577VA (en) 2017-10-30
DOP2017000212A (es) 2017-11-15
CU20170123A7 (es) 2018-02-08
IL254476A0 (en) 2017-11-30
EP3274352B1 (de) 2019-01-02
EA201792134A1 (ru) 2018-03-30
MX2017012308A (es) 2018-01-26
EP3274352A1 (de) 2018-01-31
JP2018509443A (ja) 2018-04-05
KR20170131540A (ko) 2017-11-29
WO2016150901A1 (de) 2016-09-29
CA2980646A1 (en) 2016-09-29
BR112017020317A2 (pt) 2018-06-05
PH12017501758A1 (en) 2018-04-11
CL2017002390A1 (es) 2018-05-11
TW201700480A (zh) 2017-01-01
CR20170437A (es) 2017-11-14
US10428083B2 (en) 2019-10-01
AU2016236272A1 (en) 2017-10-12
ECSP17064196A (es) 2017-10-31
CO2017009656A2 (es) 2018-01-16

Similar Documents

Publication Publication Date Title
UY36586A (es) Heterociclilmetiltienouracilos y uso de los mismos
CL2015002303A1 (es) Derivados de pirrolo[2,3-d]pirimidina
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
DOP2014000127A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2014003566A1 (es) Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
WO2015120237A3 (en) 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
WO2015042078A3 (en) Substituted aminopyrimidine compounds and methods of use
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
UY37415A (es) Tienouracilos n3-cíclicamente sustituidos y uso de los mismos
UY37016A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
MX375222B (es) Compuestos y su uso para reducir los niveles de ácido úrico
BR112016027674A2 (pt) Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas
UY35746A (es) Derivados de fenilalanina sustituidos
DOP2016000076A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
BR112013025236A2 (pt) derivados de tieno [2,3-d)pirimidina e seu uso no tratamento de arritmia
BR112018004244A2 (pt) formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso
BR112014026158A2 (pt) métodos e composições para o tratamento de infecções virais
CL2015000072A1 (es) Compuestos derivados de azaindol, inhibidores pi3k; metodo de preparacion; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento de tratornos inmunologicos, cancer y enfermedades cardiovasculares.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221104